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Sir,
Carbapenemase-producing Enterobacteriaceae, particularly
Klebsiella pneumoniae, Escherichia coli and Enterobacter spp.,
are emerging worldwide as a major public health concern.
According to the European survey on carbapenemase-producing
Enterobacteriaceae, including 38 countries in 2013 (EuSCAPE)
(http://ecdc.europa.eu/en/publications/Publications/antimicrobial-
resistance-carbapenemase-producing-bacteria-europe.pdf), the
epidemiological situation has signiﬁcantly worsened over recent
years and now represents a major threat to patient healthcare.1
Here, we identiﬁed and characterized a series of carbapenem-
resistant K. pneumoniae circulating in a single hospital in northern
Spain during a 3 month period.
All K. pneumoniae isolates with reduced susceptibility to at
least one carbapenem (imipenem and/or ertapenem) recovered
at the University Central Hospital of Asturias, northern Spain,
from September to December 2014, were selected for the
study. A total of 68 isolates were recovered from 41 patients
admitted to different wards, but only a single isolate per patient
(the ﬁrst obtained) was considered for further characterization.
These isolates were involved in urinary tract infections (33.3%),
respiratory infections (19%), sepsis (17%) and surgical wound
infections (14.3%), while 9.7% of the patients were colonized.
Antimicrobial susceptibility testing was performed by disc diffu-
sion assays (Becton Dickinson, Sparks, MD, USA), and the Microscan
System (Beckman Coulter, Brea, CA, USA) was used for determin-
ation of MICs and bacterial identiﬁcation. Susceptibility to colistin
was determined bya broth culturemicrodilutionmethod as recom-
mended by the CLSI.2 The results of susceptibility tests were inter-
preted according to CLSI breakpoints;2 however, the MICs of
tigecycline and colistin were determined and interpreted according
to EUCAST guidelines.3 The Carba NP test was applied for the detec-
tion of carbapenemase activity.4 All 41 isolates were resistant to
amoxicillin/clavulanate and piperacillin/tazobactam. In addition,
all showed reduced susceptibility or resistance to ertapenem and
imipenem, except 15 isolates (36.6%) that remained susceptible
to imipenem. Interestingly, nine isolates (21.9%) were resistant
to cefoxitin, and resistance to broad-spectrum cephalosporins
was observed in all but one isolate (97.6%). Additionally, 93% of
the isolates were resistant to ciproﬂoxacin, 78% to trimethoprim/
sulfamethoxazole, 68% to gentamicin, 80% to tobramycin, 41%
to amikacin, 20% to tigecycline, 7% to fosfomycin and 10% to
colistin. The Carba NP test was positive for all 41 isolates.
Genes encoding resistance to carbapenems (blaOXA-48, blaNDM,
blaVIM, blaKPC, blaIMP) and to broad-spectrum cephalosporins
(blaCTX-M, blaSHV) were screened by PCR ampliﬁcation followed by
sequencing.5 PCRs were also performed to determine the genetic
environment of the blaOXA-48 gene.
6 All isolates were positive for
the blaOXA-48 carbapenemase gene that was located in trans-
poson Tn1999.2.6 In addition, 80% of the isolates resistant to
broad-spectrum cephalosporins were positive for the blaCTX-M-15
gene, while the remaining 20%were positive for the blaSHV-12 gene.
Conjugation assays were performed using each of the
blaOXA-48-positive isolates as donors and E. coli J53 resistant to
sodium azide as the recipient strain. Transconjugants were
selected on eosin methylene blue agar containing sodium azide
(100 mg/L) plus temocillin (50 mg/L). Plasmid DNAwas extracted
using the Kado and Liu technique and the incompatibility group of
the blaOXA-48-carrying plasmids was established, as previously
described.5 The blaOXA-48 gene was carried by a conjugative plas-
mid of 62 kb belonging to the IncL/M group, corresponding to
the epidemic plasmid bearing the blaOXA-48 gene.
7 The remaining
b-lactamase genes identiﬁed among the OXA-48 producers were
always carried on distinct plasmids. To establish the genetic rela-
tionships between the isolates, 25 of them, selected as represen-
tatives of the different resistance phenotypes and hospital wards
(Figure 1), were analysed by PFGE performed using endonuclease
XbaI (www.pulsenetinternational.org). Overall, 19 different PFGE
proﬁles were identiﬁed, with similarities evaluated by the Dice
coefﬁcient and cluster analysis performed using the software
program MVSP (Multivariate Statistics Package for PCs, RockWare
Inc.). Using a coefﬁcient of similarity of 0.85, the 19 proﬁles could
be distributed into six clusters termed CX1–CX6. One isolate per
cluster was typed by MLST according to the Pasteur Institute
scheme (www.pasteur.fr/mlst), giving rise to the subsequent
clones ST326 (CX1), ST405 (CX2), ST147 (CX3), ST104 (CX4 and
CX5) and ST15 (CX6) (Figure 1). Of note, all clones except ST104
had previously been associated with OXA-48 production in
Europe and/or Spain.1,8,9
The concomitant occurrence of ﬁve different K. pneumoniae
clones producing OXA-48 in a single hospital might be explained,
at least in part, by the high transfer frequency of the IncL/M plas-
mid carrying the blaOXA-48 gene.
10 In view of our data, it is likely
that the spread of OXA-48-producing K. pneumoniae in Spain
will rapidly mirror the endemic situation observed in Italy and
the USA with KPC-producing K. pneumoniae isolates. Once again,
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Figure 1. Dendrogram showing the relationships between 25 OXA-48-producing isolates of K. pneumoniae (Kp), selected as representative of different antimicrobial resistance
phenotypes and hospital wards. In all isolates, the blaOXA-48 gene was carried by an 62 kb conjugative IncL/M plasmid, and associated with transposon Tn1999.2. I, intermediate
resistance; AMX, amoxicillin; AMC, amoxicillin/clavulanate; CTX, cefotaxime; TEM, temocillin; ETP, ertapenem; IPM, imipenem; GEN, gentamicin; TOB, tobramycin; CIP, ciproﬂoxacin;
SXT, trimethoprim/sulfamethoxazole; AMK, amikacin; TGC, tigecycline; FOF, fosfomycin; FOX, cefoxitin; CST, colistin; CARB, carbapenemase.
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this bacterial species is playing a pivotal role in the emergence and
dispersion of resistance traits in hospital settings. Urgent hygiene
measures have to be taken to prevent further consolidation of a
difﬁcult-to-control situation.
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